Multiple Sclerosis: Oxford Neurology Library
Autor Neil Scolding, Alastair Wilkinsen Limba Engleză Paperback – 4 iul 2012
Preț: 252.58 lei
Preț vechi: 284.92 lei
-11% Nou
Puncte Express: 379
Preț estimativ în valută:
48.34€ • 49.87$ • 40.91£
48.34€ • 49.87$ • 40.91£
Carte tipărită la comandă
Livrare economică 21-27 februarie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780199603251
ISBN-10: 0199603251
Pagini: 90
Ilustrații: numerous illustrations
Dimensiuni: 131 x 195 x 5 mm
Greutate: 0.11 kg
Editura: OUP OXFORD
Colecția OUP Oxford
Seria Oxford Neurology Library
Locul publicării:Oxford, United Kingdom
ISBN-10: 0199603251
Pagini: 90
Ilustrații: numerous illustrations
Dimensiuni: 131 x 195 x 5 mm
Greutate: 0.11 kg
Editura: OUP OXFORD
Colecția OUP Oxford
Seria Oxford Neurology Library
Locul publicării:Oxford, United Kingdom
Notă biografică
Neil Scolding qualified in medicine in Cardiff in 1982, and then completed a PhD in 1989, also in Cardiff. He trained in neurology in Cardiff, in Cambridge, and at the National Hospital for Neurological Diseases in London, then was a Consultant Senior Lecturer in Neurology at Addenbrooke's Hospital in Cambridge in 1996. In 1999 he moved to Bristol as the foundation chair-holder in the Burden Professorship of Clinical Neurosciences. He has established a research team in Bristol at Frenchay Hospital whose main focus of interest continues to be multiple sclerosis - more specifically, developing and testing adult stem cell therapy for MS. Dr Alastair Wilkins is Senior Lecturer in Neurology, University of Bristol and Honorary Consultant Neurologist at Frenchay Hospital, Bristol. He trained in medicine at Cambridge University, where he also did a PhD concerned with mechanisms of axon degeneration in multiple sclerosis. His neurology training was in Norwich, Cambridge and the National Hospital for Neurology, Queen Square, London. He has done post-doctoral research at University of Cambridge and the University of Wisconsin-Madison, USA. His research interests include understanding disease mechanisms in progressive multiple sclerosis and design of new therapies for this stage of the disease.